Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 29.46% is in line with its 5-year average of 31.05%, near the low end of its 5-year range (27.55%–35.02%).
As of the fiscal period ended Tuesday, March 31, 2026. 3.36% below its 12-month average of 30.48%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
29.46%
EBITDA MARGIN AVG TTM
30.48%
EBITDA MARGIN AVG 3Y
31.38%
EBITDA MARGIN AVG 5Y
31.05%
EBITDA MARGIN AVG 10Y
28.59%
EBITDA MARGIN AVG 15Y
26.02%
EBITDA MARGIN AVG 20Y
23.91%
CURRENT VS TTM AVG
-3.36%
CURRENT VS 3Y AVG
-6.14%
CURRENT VS 5Y AVG
-5.12%
CURRENT VS 10Y AVG
+3.02%
CURRENT VS 15Y AVG
+13.20%
CURRENT VS 20Y AVG
+23.22%
Mettler-Toledo International Inc.
Market Cap
$26.82B
EBITDA Margin
29.46%
TTM Avg
30.48%
3Y Avg
31.38%
5Y Avg
31.05%
Market Cap
$27.56B
EBITDA Margin
16.19%
TTM Avg
16.24%
3Y Avg
16.31%
5Y Avg
17.37%
Market Cap
$25.15B
EBITDA Margin
19.69%
TTM Avg
19.16%
3Y Avg
18.89%
5Y Avg
21.02%
Market Cap
$24.42B
EBITDA Margin
34.73%
TTM Avg
34.58%
3Y Avg
34.05%
5Y Avg
33.84%
Market Cap
$24.34B
EBITDA Margin
15.75%
TTM Avg
14.53%
3Y Avg
14.10%
5Y Avg
17.90%
Market Cap
$23.51B
EBITDA Margin
27.93%
TTM Avg
16.21%
3Y Avg
17.95%
5Y Avg
14.24%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mettler-Toledo International Inc. (MTD) | $26.82B | 29.46% | 30.48% | 31.38% | 31.05% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $27.56B | 16.19% | 16.24% | 16.31% | 17.37% |
| DexCom, Inc. (DXCM)vs › | $27.61B | 24.96% | 22.62% | 21.42% | 19.95% |
| ResMed Inc. (RMD)vs › | $28.33B | 37.33% | 35.06% | 33.74% | 33.79% |
| Quest Diagnostics Incorporated (DGX)vs › | $25.15B | 19.69% | 19.16% | 18.89% | 21.02% |
| Waters Corporation (WAT)vs › | $24.42B | 34.73% | 34.58% | 34.05% | 33.84% |
| Labcorp Holdings Inc. (LH)vs › | $24.34B | 15.75% | 14.53% | 14.10% | 17.90% |
| Biogen Inc. (BIIB)vs › | $29.85B | 28.67% | 30.68% | 30.30% | 31.44% |
| Incyte Corporation (INCY)vs › | $23.51B | 27.93% | 16.21% | 17.95% | 14.24% |
| West Pharmaceutical Services, Inc. (WST)vs › | $23.10B | 24.13% | 25.03% | 27.36% | 27.53% |
Gross Margin
57.8%
EBITDA Margin
29.5%
Operating Margin
28.0%
Net Margin
21.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | 29.46% |
| 2025-12-31 | 33.29% |
| 2025-09-30 | 31.33% |
| 2025-06-30 | 30.12% |
| 2025-03-31 | 28.20% |
| 2024-12-31 | 34.88% |
| 2024-09-30 | 32.41% |
| 2024-06-30 | 31.31% |
| 2024-03-31 | 30.22% |
| 2023-12-31 | 31.48% |
| 2023-09-30 | 32.70% |
| 2023-06-30 | 32.57% |
| 2023-03-31 | 29.98% |
| 2022-12-31 | 35.02% |
| 2022-09-30 | 32.34% |
| 2022-06-30 | 30.34% |
| 2022-03-31 | 28.19% |
| 2021-12-31 | 31.87% |
| 2021-09-30 | 29.83% |
| 2021-06-30 | 28.84% |
| 2021-03-31 | 27.55% |
| 2020-12-31 | 32.40% |
| 2020-09-30 | 29.80% |
| 2020-06-30 | 27.05% |
| 2020-03-31 | 23.32% |
| 2019-12-31 | 31.51% |
| 2019-09-30 | 27.35% |
| 2019-06-30 | 25.62% |
| 2019-03-31 | 23.20% |
| 2018-12-31 | 30.44% |
| 2018-09-30 | 26.03% |
| 2018-06-30 | 24.76% |
| 2018-03-31 | 22.50% |
| 2017-12-31 | 29.16% |
| 2017-09-30 | 24.36% |
| 2017-06-30 | 23.77% |
| 2017-03-31 | 22.76% |
| 2016-12-31 | 29.06% |
| 2016-09-30 | 24.36% |
| 2016-06-30 | 22.53% |
| 2016-03-31 | 20.41% |
| 2015-12-31 | 28.26% |
| 2015-09-30 | 23.60% |
| 2015-06-30 | 21.76% |
| 2015-03-31 | 19.71% |
| 2014-12-31 | 26.44% |
| 2014-09-30 | 21.51% |
| 2014-06-30 | 19.94% |
| 2014-03-31 | 18.05% |
| 2013-12-31 | 25.39% |
| 2013-09-30 | 21.07% |
| 2013-06-30 | 19.87% |
| 2013-03-31 | 17.99% |
| 2012-12-31 | 24.73% |
| 2012-09-30 | 20.29% |
| 2012-06-30 | 17.72% |
| 2012-03-31 | 16.54% |
| 2011-12-31 | 21.23% |
| 2011-09-30 | 17.81% |
| 2011-06-30 | 16.85% |
| 2011-03-31 | 16.27% |
| 2010-12-31 | 22.39% |
| 2010-09-30 | 19.08% |
| 2010-06-30 | 18.55% |
| 2010-03-31 | 16.30% |
| 2009-12-31 | 264.56% |
| 2009-09-30 | 18.54% |
| 2009-06-30 | 16.93% |
| 2009-03-31 | 15.87% |
| 2008-12-31 | 21.14% |
| 2008-09-30 | 16.44% |
| 2008-06-30 | 16.08% |
| 2008-03-31 | 14.94% |
| 2007-12-31 | 19.25% |
| 2007-09-30 | 16.58% |
| 2007-06-30 | 16.32% |
| 2007-03-31 | 14.23% |
| 2006-12-31 | 18.23% |
| 2006-09-30 | 15.66% |
| 2006-06-30 | 15.63% |
| 2006-03-31 | 12.89% |
| 2005-12-31 | 18.31% |
| 2005-09-30 | 15.67% |
| 2005-06-30 | 15.69% |
| 2005-03-31 | 12.55% |
| 2004-12-31 | 16.54% |
| 2004-09-30 | 13.92% |
| 2004-06-30 | 15.44% |
| 2004-03-31 | 12.33% |
| 2003-12-31 | 16.29% |
| 2003-09-30 | 14.33% |
| 2003-06-30 | 15.39% |
| 2003-03-31 | 12.57% |
| 2002-12-31 | 17.16% |
| 2002-09-30 | 15.27% |
| 2002-06-30 | 15.94% |
